Ушбу иш иқтибос қилган ишлар

30 та иш

Иш: Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Armand Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim +4
Мақола201011 иқтибос
ABI
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Andrew Nunn, Patrick Phillips, Sarah Meredith +16
Мақола20196 иқтибос
ABI
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses
Alberto Piubello, Souleymane Hassane Harouna, Mahamadou Bassirou Souleymane +5
Мақола20146 иқтибос
ABI
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries
Arnaud Trébucq, V Schwoebel, Zacharie Kashongwe +15
Мақола20176 иқтибос
ABI
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon
Christopher Kuaban, J Noeske, Hans L. Rieder +3
Мақола20155 иқтибос
ABI
Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
Shona Horter, Beverley Stringer, Jane Greig +5
МақолаTuberculosis Research and EpidemiologyBMC Infectious Diseases20164 иқтибос
ABI
Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses
Faiz Ahmad Khan, M Salim, Philipp du Cros +9
Шарҳ мақолаTuberculosis Research and EpidemiologyEuropean Respiratory Journal20174 иқтибос
ABI
An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis
Mayara Lisboa Bastos, Zhiyi Lan, Dick Menzies
Шарҳ мақола20174 иқтибос
ABI
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
Nafees Ahmad, Shama D. Ahuja, Onno W. Akkerman +97
Шарҳ мақола20184 иқтибос
ABI
Risk Factors Associated with Default from Multi- and Extensively Drug-Resistant Tuberculosis Treatment, Uzbekistan: A Retrospective Cohort Analysis
Maeve K. Lalor, Jane Greig, Sholpan Allamuratova +6
Мақола20134 иқтибос
ABI
Prediction of Creatinine Clearance from Serum Creatinine
Donald W. Cockcroft, Henry Gault
Мақола20083 иқтибос
ABI
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance
J. Peter Cegielski, Ekaterina V. Kurbatova, Martie van der Walt +74
Мақола20153 иқтибос
ABI
WHO recommendations on shorter treatment of multidrug-resistant tuberculosis
Giovanni Sotgiu, Simon Tiberi, Lia D’Ambrosio +3
Мақола20162 иқтибос
ABI
Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations
Francis Varaine, Lorenzo Guglielmetti, Helena Huerga +5
Бошқа20162 иқтибос
ABI
Preferential adherence to antiretroviral therapy over tuberculosis treatment: A qualitative study of drug-resistant TB/HIV co-infected patients in South Africa
Amrita Daftary, Nesri Padayatchi, Max R. O’Donnell
Мақола20142 иқтибос
ABI
Research Protocol - Effectiveness of a simplified short regimen for Multidrug Resistant Tuberculosis treatment in Karakalpakstan, Uzbekistan
Philipp du Cros, Khamraev Atadjan, Mirzagalib Tillashaikhov +19
Мақола20142 иқтибос
ABI
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
Christoph Lange, Raquel Duarte, M. Jachym +7
Бошқа20162 иқтибос
ABI
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Dennis Falzon, Holger J. Schünemann, Elizabeth Harausz +4
Мақола20172 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI